AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our focus is acute on chronic kidney injury, impacting hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for acute kidney injury and its safety and a potential reno-protective effect has been demonstrated in global clinical trials involving approximately 1,000 subjects. In addition, based upon preclinical data showing improved overall survival and restored phenotypes associated with hypophosphatasia (HPP) as well as a biomarker dose response in adult patients with HPP treated with ilofotase alfa, we are developing ilofotase alfa as a potential enzyme replacement therapy in HPP. We are a dedicated team driven to bring treatment options to severely ill patients, their families and health care professionals.
AM-Pharma, founded in 2001 and based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa, for treatment of acute on chronic kidney injury and the rare disease hypophosphatasia.
AM-Pharma strives to develop medicines for patients confronted with severe medical conditions. Our proprietary asset, ilofotase alfa, is being developed for the treatment of patients with acute on chronic kidney injury and has been granted FDA fast-track status and for patients with hypophosphatasia, an orphan disease for which we have orphan drug designation granted by the FDA and EMA.
At AM-Pharma we work together in a constructive, collaborative and team-oriented way, towards achieving the company objectives without losing sight of our own objectives. We put the common interest of the patients and the company above our own individual interest.
We set high standards regarding the quality of our materials, processes, documentation and collaborations, the staff are motivated to deliver excellence whilst also working to continually improve the quality of our work.
We are fully accountable for the things that are in our power and control while working towards the goals of the organization. We have an obligation to proactively report, explain and justify the things we do. We accept responsibility for our performance and we are transparent about the results of our work.
We understand how to cope effectively with setbacks and obstacles and overcome hurdles on our way to reach our common goals. We stay committed to agreed objectives and company culture despite resistance while having the strength to adjust our plans when necessary. We are tolerant to stress and we deal effectively with criticism and resistance, building on our own strength.
Mark Altmeyer, MBA - Chairman of the Board
Prior to joining AM-Pharma’s Supervisory Board, Mark Altmeyer was founder, President and Chief Executive Officer at Arvelle Therapeutics, in addition to serving as Executive Director of Arvelle’s Board of Directors. At Arvelle, he led the development of the company until its acquisition by Angelini for USD 1 billion. In advance of that transaction, he established Arvelle’s global headquarters in Switzerland, secured USD 200 million initial funding and built the European team to over 100 employees in under two years. Before Arvelle, Mark served as President and Chief Commercial Officer at Axovant Sciences, where he was responsible for establishing Axovant’s global commercial capabilities and launch preparations for various pipeline products. Earlier in his career, Mark served as President and CEO at Otsuka America Pharmaceutical, leading the transformation into a successful commercial organization, doubling total revenues from USD 2.5 billion to nearly 5 billion in five years. Mark held senior commercial and business development positions at Bristol-Myers Squibb, Cetus Corporation and Bristol Labs in the United States. He holds an MBA from Harvard Graduate School of Business and a BA in economics from Middlebury College.
Martijn Kleijwegt, MSc
Martijn Kleijwegt, is a Managing Partner and Founder at LSP and a pioneer in the European life sciences arena. He was instrumental in the successes of Prosensa (NL, IPO in 2013, sold to Biomarin for €548 million in 2015), Movetis (BEL, IPO in 2009, sold to Shire for €428 million in 2010), Crucell (NL, IPO in 2000, sold to Johnson & Johnson for €1.75 billion in 2011), Rhein Biotech (NL, IPO in 1999, sold to Berna Biotech for €279 million in 2002), and Qiagen (GER, IPO in 1996, valued 30 June 2017 at €6.6 billion).
After starting his career at Philips, he gained extensive experience in the life sciences sector as General Partner of Euroventures Benelux, one of the first venture funds in Europe with life sciences in its investment scope. Martijn led the life sciences investment strategy and built the Euroventures Life Sciences (ELS) fund. In 1998, Martijn founded LSP and together with the other general partners built it into what it is today. Martijn currently represents LSP on the supervisory boards of Kiadis Pharma (NL), OxThera (SE), Orphazyme (DK), Pharvaris (GER), Arvelle therapeutics (NL/CH) and Eloxx Pharmaceuticals (USA/IS).
He holds a Master’s degree in Economics from Amsterdam University.
Raphaël Wisniewski, MSc
Raphaël Wisniewski is a Managing Partner at Andera Partners (formerly Edmond de Rothschild Investment Partners).
Raphaël serves as a Director on the Board of ReViral, MedDay Pharmaceuticals, Artios Pharma, Dynacure, Grey Wolf, Axonics Modulation and as an observer on the Boards of Poxel and Enyo. Previously, he worked in Healthcare Corporate Finance at Goldman Sachs starting at Salomon Smith Barney. He was also in the Finance Departments of Health in London and in the Department of General Healthcare in London, the private hospital group.
Raphaël is a graduate of the Ecole des Hautes Etudes Commerciales, Paris, and holds a Master’s degree in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris.
Geert-Jan Mulder, MD
Geert-Jan Mulder is a Managing Partner at Forbion.
He currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio, which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics, which went public in 2006 and where he was part of the AMPYRA® (dalfampridine) board panel to evaluate a new regulatory endpoint in Multiple Sclerosis, PanGenetics B.V., Transave, and Exosome Diagnostics. In addition, he is a co-author of several Forbion and Forbion portfolio related scientific publications.
Geert-Jan received his MD from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC).
Rémi Droller, MSc
Rémi Droller is a Managing Partner of Kurma Partners.
Prior to that, he held positions at CDC Innovation from 2000 to 2003 and at AGF Private Equity (now Idinvest Partners) from 2003 to 2010, where he was in charge of developing the life sciences investment activity. Rémi serves on the Board of Dynacure (France), ImCheck Therapeutics (France), Orphazyme (Denmark – listed on the Copenhagen Stock Exchange), Oxthera (France) and Pharvaris (the Netherlands).
Rémi has a Master’s degree in Molecular Biology (Paris VI University) and a Master’s degree in Finance and Innovation Management (AgroPariTech).
Erik van den Berg, MSc, MBA
Erik served as CEO at AM-Pharma from 2011 through 2023 and has over 25 years’ experience.
Erik is Chairman of Step Pharma and TargED Biopharmaceuticals and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead Pharma and the Dutch biotechnology organization.
As Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis (SWX/Euronext: ISON – sold to Integra Lifesciences), and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, including a $600M alliance with Pfizer, $290M partnership with Kyowa Kirin and raised ~€500M in equity and debt financing for biotechnology companies from seed through IPO.
Erik holds a Master’s degree in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).
Joël Jean-Mairet, PhD (Board Observer)
Joël is managing partner and co-founder of Ysios Capital.
Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. He holds an MS in Biotechnology and a PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.
Joël is currently on the boards of directors of Adcendo, SpliceBio, ONA, board observed at Mineralys and Executive Chairman of Inbiomotion. He has been Chairman of the board of Cellerix/Tigenix (now Takeda), board member of Aura Biosciences (Nasdaq: AURA), LAVA Therapeutics (Nasdaq: LVTX) and Sanifit Therapeutics (now Vifor Pharma), and board observer at Biovex (now Amgen). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.
AM-Pharma, founded in 2001 and based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa, for treatment of acute and chronic kidney injury and the rare disease hypophosphatasia (HPP).
Details of current vacancies – if any – are listed on this page. To apply, please send your CV and cover letter, stating the title of the position you are applying for, to hr@am-pharma.com.
